» Articles » PMID: 27712705

First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment

Overview
Journal Value Health
Publisher Elsevier
Date 2016 Oct 8
PMID 27712705
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There has been tremendous progress regarding treatment options for hepatitis C virus (HCV) infection. Several interferon-free regimens are awaiting regulatory approval. These innovations promise substantial reductions in the burden of disease and side effects as well as a decrease in treatment duration.

Objectives: The aim of this quantitaitive study was to elicit patient preferences for attributes of innovative antiviral therapies for hepatitis C.

Methods: A systematic literature search and 14 semi-structured interviews were performed, resulting in eight patient-relevant characteristics. For the discrete choice experiment, an experimental design (3×3 + 5×6) was generated using Ngene software. The survey was conducted in August 2014 through computer-assisted personal interviews. The data were effects-coded in a random parameter logit estimation.

Results: Participants were patients with HCV (N = 561; 58.1% men) in different treatment states. The analysis revealed a predominance of the attribute "reaching sustained virological response." When considering confidence intervals, the results showed three different preference ranks. At first place was "sustained virological response" (level difference [LD] 3.98), second was "anemia" (LD 1.10), followed by "number of interferon injections" (LD 0.92), "rash" (LD 0.82), "nausea and/or diarrhea" (LD 0.79), and "duration of antiviral therapy" (LD 0.78). The last position was occupied by both "tiredness/fatigue" (LD 0.31) and "headache" (LD 0.34).

Conclusions: From the patients' point of view, sustained virological response is the most essential criterion for choosing an HCV therapy. It was ranked at the highest, dominating all side effects and modes of administration. Furthermore, this study proved that patients consider both the probability of occurrence and the severity of treatment-induced side effects. Results clearly point to valuation of probabilities that is separate from that of severity.

Citing Articles

Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

El Masri H, McGuire T, Dalais C, van Driel M, Benham H, Hollingworth S J Med Libr Assoc. 2022; 110(2):185-204.

PMID: 35440905 PMC: 9014953. DOI: 10.5195/jmla.2022.1306.


Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".

Muhlbacher A, Sadler A PLoS One. 2021; 16(2):e0245480.

PMID: 33600462 PMC: 7891755. DOI: 10.1371/journal.pone.0245480.


Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure.

Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester S Patient Prefer Adherence. 2020; 14:613-624.

PMID: 32256052 PMC: 7090182. DOI: 10.2147/PPA.S238833.


Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review.

Ver Donck N, Vander Stichele G, Huys I Interact J Med Res. 2020; 9(1):e13684.

PMID: 32229460 PMC: 7157502. DOI: 10.2196/13684.


What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism.

Mattingly 2nd T, Slejko J, Perfetto E, Kottilil S, Daniel Mullins C Patient. 2019; 12(6):631-638.

PMID: 31347011 DOI: 10.1007/s40271-019-00378-7.